Evaluation of Optic Neuritis Using Synthetic Quantitative MRI
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MRI sequence.
- Who it may be relevant to
- Registry conditions: Optic Neuritis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Inflammatory optic neuropathy (optic neuritis) is an acute condition that can affect the optic nerve along its entire course. It is a rare event, with a prevalence of up to 5 cases per 100,000 people per year, predominantly affecting young individuals (18-50 years old), primarily Caucasian and female. The causes of optic neuropathy are diverse, with the most common being multiple sclerosis, which is the revealing condition in nearly 30% of cases. MRI is an integral part of the initial assessment of optic neuritis, in conjunction with clinical examination, laboratory tests, and OCT (optical coherence tomography). It plays a crucial role in the acute management of this condition, particularly by guiding the etiological diagnosis and helping adapt the therapeutic approach accordingly. The establishment of objective and reliable MRI prognostic markers could allow for more precise immediate therapeutic adjustments, thereby improving the prognosis of this potentially severe and debilitating disease, whose treatment itself is not without risks. Indeed, determining the appropriate corticosteroid dose and deciding whether to combine it with other treatments remains a current clinical challenge. Despite various publications, MRI prognostic criteria for short- and long-term outcomes of optic neuritis remain unclear. Recent studies using radiomics have shown promising results, but these rely on limited sample sizes. New investigative methods are currently under development in the field of medical imaging, particularly "quantitative MRI." This approach enables effective analysis through mapping techniques, which generate numerical values compared to predetermined references. For instance: T1 (or R1) mapping assesses fibrosis and, indirectly, myelination, T2 (or R2) mapping evaluates edema. To our knowledge, this approach has never been studied for the optic nerve. More recently, the emergence of synthetic imaging has made it possible to generate the previously mentioned R1/R2 maps, along with more conventional weighted images (T1, T2, FLAIR, DP), from a single MRI sequence (2D spin-echo sequence). This sequence provides quantitative values while maintaining a short acquisition time (\~5 minutes), which is essential in ophthalmologic imaging, where motion artifacts are frequent. The goal of this study is to identify prognostic criteria for the evolution of optic neuritis using synthetic quantitative MRI sequences, in the form of threshold numerical values.
Interventions
- Other MRI sequence
This sequence is a 2D spin-echo sequence for the generation of synthetic maps
Primary outcome measures
- visual function at 4 months (ordinal outcome) [Time frame: 4 months after inclusion]
Eligibility criteria
Inclusion criteria
- Presenting with a painful unilateral decrease in visual acuity for less than one month
- Referred for contrast-enhanced MRI imaging
- Explicit consent for participation in the study
Exclusion criteria
- Ophthalmological diagnosis other than optic neuritis explaining the symptoms
- Known history of optic neuritis (same eye or contralateral eye)
- Ophthalmological history interfering with the interpretation of ophthalmologic examinations (severe myopia, retinopathy)
- Known glaucoma (same eye or contralateral eye)
- Known diabetes
- Patient under legal protection
- Pregnant or breastfeeding woman
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06916182 · ALR_2024_11